vaccine

May 27, 2020 | 9:12am | Updated May 27, 2020 | 9:34am Nikolai Petrovsky Flinders University The P4 laboratory at the Wuhan Institute of Virology. AFP via Getty Images Up Next You ask, we answer. The Post is fielding questions from... The coronavirus that causes COVID-19 is “almost perfectly human adapted” — lending credence to…

a backlash was underway. The company had not released any more data, so scientists could not evaluate its claim. The government agency leading the trial, the National Institute of Allergy and Infectious Diseases, had made no comment on the results. And the stock sale stirred concerns about whether the company had sought to jack up…

Coronavirus vaccine candidate Ad5-nCoV from Chinese pharmaceutical company CanSino is both safe and effective, according to the results of a Phase 1 clinical trial. Researchers looking at 108 healthy volunteers who received the test drug in mid-March found the vaccine generates the kind of immune response that can kill the novel coronavirus. The side-effects were…

May 22, 2020 | 3:15pm | Updated May 22, 2020 | 3:36pm The first COVID-19 vaccine to reach clinical trials in humans was determined to be both safe and generate an immune response against the virus — a “milestone” in the battle to defeat the deadly bug, a new study found. A single dose of…

An engineer shows a plastic model of the Covid-19 coronavirus at the Quality Control Laboratory at the Sinovac Biotech facilities in Beijing.Nicolas Asfouri | AFP | Getty ImagesA potential coronavirus vaccine developed in China appeared to provoke neutralizing antibodies in dozens of patients in an early-stage clinical trial, an important step in developing a vaccine…